Compile Data Set for Download or QSAR
maximum 50k data
Found 49 of ph data with Target = 'RAF proto-oncogene serine/threonine-protein kinase'
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM16673(4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamo...)
Affinity DataIC50:  1nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMedDrugBank

TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26023(4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzod...)
Affinity DataIC50:  1nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26028(4-({2-[(3-tert-butylphenyl)(methyl)amino]-1H-1,3-b...)
Affinity DataIC50:  4nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26022(4-({2-[(3-bromophenyl)(methyl)amino]-1H-1,3-benzod...)
Affinity DataIC50:  4nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26025(N-methyl-4-[(2-{methyl[3-(trifluoromethyl)phenyl]a...)
Affinity DataIC50:  6nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26017(4-({2-[(3-tert-butylphenyl)amino]-1H-1,3-benzodiaz...)
Affinity DataIC50:  8nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26029(4-({2-[(4-tert-butylphenyl)(methyl)amino]-1H-1,3-b...)
Affinity DataIC50:  9nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26026(N-methyl-4-[(2-{methyl[4-(trifluoromethyl)phenyl]a...)
Affinity DataIC50:  9nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26021(4-({2-[(2-bromophenyl)(methyl)amino]-1H-1,3-benzod...)
Affinity DataIC50:  10nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26032(N-methyl-4-[(2-{methyl[3-(pyridin-4-yl)phenyl]amin...)
Affinity DataIC50:  10nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26018(4-({2-[(4-tert-butylphenyl)amino]-1H-1,3-benzodiaz...)
Affinity DataIC50:  15nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26020(4-[(2-{[4-chloro-3-(trifluoromethyl)phenyl](methyl...)
Affinity DataIC50:  15nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26033(4-({2-[(4-bromophenyl)(ethyl)amino]-1H-1,3-benzodi...)
Affinity DataIC50:  18nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26013(4-({2-[(4-bromophenyl)amino]-1H-1,3-benzodiazol-5-...)
Affinity DataIC50:  19nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26016(N-methyl-4-[(2-{[4-(trifluoromethyl)phenyl]amino}-...)
Affinity DataIC50:  20nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26031(4-({2-[(cyclohexylmethyl)(methyl)amino]-1H-1,3-ben...)
Affinity DataIC50:  28nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM50436431(CHEMBL2397149 | US9029401, 2576)
Affinity DataIC50:  30nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26009(4-({2-[(4-bromophenyl)amino]-1-methyl-1H-1,3-benzo...)
Affinity DataIC50:  45nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM16673(4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamo...)
Affinity DataIC50:  45nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26019(N-methyl-4-({2-[methyl(phenyl)amino]-1H-1,3-benzod...)
Affinity DataIC50:  48nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26015(N-methyl-4-[(2-{[3-(trifluoromethyl)phenyl]amino}-...)
Affinity DataIC50:  56nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158488(US9029401, 2278 (t-CUPM))
Affinity DataIC50:  75nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM17678(2-aminobenzimidazole, 3 | 4-[(2-{[4-chloro-3-(trif...)
Affinity DataIC50:  76nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26027(4-({2-[(2-tert-butylphenyl)(methyl)amino]-1H-1,3-b...)
Affinity DataIC50:  150nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26024(N-methyl-4-[(2-{methyl[2-(trifluoromethyl)phenyl]a...)
Affinity DataIC50:  150nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM50436438(CHEMBL2397146 | US9029401, 2316)
Affinity DataIC50:  175nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26012(4-({2-[(3-bromophenyl)amino]-1H-1,3-benzodiazol-5-...)
Affinity DataIC50:  210nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158485(US10383835, Compound 2228 | US9029401, 2227)
Affinity DataIC50:  340nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26011(4-({2-[(2-bromophenyl)amino]-1H-1,3-benzodiazol-5-...)
Affinity DataIC50:  490nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158489(US9029401, 2280)
Affinity DataIC50:  550nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26014(N-methyl-4-[(2-{[2-(trifluoromethyl)phenyl]amino}-...)
Affinity DataIC50:  950nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26030(4-({2-[cyclohexyl(methyl)amino]-1H-1,3-benzodiazol...)
Affinity DataIC50:  1.10E+3nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158493(US9029401, 2319 (c-CUPM))
Affinity DataIC50:  1.50E+3nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26008(4-{4-[(5-chloro-1H-1,3-benzodiazol-2-yl)amino]phen...)
Affinity DataIC50:  2.00E+3nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM26010(N-methyl-4-{[2-(phenylamino)-1H-1,3-benzodiazol-5-...)
Affinity DataIC50:  3.50E+3nMpH: 7.8 T: 2°CAssay Description:To measure compound inhibitor effects on the ability of Raf enzymes to phosphorylate the Mek substrate, a capture ELISA utilizing streptavidin-coated...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158484(US9029401, 2221)
Affinity DataIC50:  4.30E+3nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158481(US9029401, 1728 (t-TUCB))
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM50436432(CHEMBL2397136 | US9029401, 2287)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158490(US9029401, 2288)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158491(US9029401, 2315)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158478(US10189853, sunitinib | US9029401, Sunitinib | US9...)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158494(US9029401, 2372)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158495(US9029401, 2574)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM50436441(CHEMBL2397143 | US9029401, 2575)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158482(US9029401, 2084)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM50436435(CHEMBL2397139 | US9029401, 2225)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM158486(US9029401, 2228)
Affinity DataIC50: >1.00E+4nMpH: 7.5Assay Description:Inhibitor Concentration at 50% enzyme inhibition (IC50) values were calculated by quantifying the end-point ADP production from each kinase reaction ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM206291(4-((2-((3-(Tert-butyl)phenyl)amino)quinolin-5-yl)o...)
Affinity DataIC50:  9.26E+4nMpH: 7.5 T: 2°CAssay Description:Reaction Biology Corporation Kinase HotSpotSM service: In a final reactionvolume of 25 μL, kinase (5-10 mU) is incubated with 25 mM Tris pH 7.5,...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Novartis

LigandPNGBDBM206292(4-((2-((4-Chloro-3-(trifluoromethyl)phenyl)amino)q...)
Affinity DataIC50: >1.00E+5nMpH: 7.5 T: 2°CAssay Description:Reaction Biology Corporation Kinase HotSpotSM service: In a final reactionvolume of 25 μL, kinase (5-10 mU) is incubated with 25 mM Tris pH 7.5,...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed